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ABSTRACT 
Objectives: Patient-relevant measures of functional status are required in chronic obstructive 
pulmonary disease (COPD) and lung cancer in clinical practice and research.  We explored the 
relationship between the Australia-modified Karnofsky Performance Status (AKPS) and measures 
of functional capacity and physical activity in these patient groups. 
Methods: Pooled clinical trial data were analysed to explore the relationship between AKPS and: 
average daily steps [ADS], 6-minute walk distance [6MWD] and BODE score (COPD group). 
Receiver Operator Characteristic curves were produced to compare sensitivity and specificity of 
cut-offs (no dependency >70; high dependency <60) and area under the curve (AUC). 
Results: Seven clinical trials included people with COPD (n=79) and lung cancer (n=150). To 
detect an AKPS >70, the optimal ADS cut-points were COPD, 3342 steps (AUC; 0.88, 95% CI: 
0.79, 0.97; sensitivity 82%; specificity 76%) and lung cancer, 3380 steps (AUC 0.72, 95% CI: 0.64-
0.81; sensitivity 61%; specificity 74%), and for 6MWD (COPD only) 242m (AUC 0.72, 95% CI 
0.63, 0.81; sensitivity 73%; specificity 34%).  
Conclusions: An AKPS score is strongly related to ADS in people with COPD and lung cancer. 
The AKPS may be useful in clinical practice and research to indicate levels of physical activity 
where ADS and 6MWT are not possible. Longitudinal data are needed to confirm these findings. 
. 
Keywords: physical activity, chronic obstructive pulmonary disease, Lung Cancer, performance 
status, outcome measurement, functional independence 
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INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of morbidity, 
mortality and resource use worldwide. There are international calls for systematic research to 
improve symptom management, especially for chronic breathlessness.[1] Outcome measures must 
matter to patients, be minimally burdensome and reflect meaningful gain, especially for those with 
advanced disease.  
The Six Minute Walk Distance (6MWD) is widely used in COPD to evaluate functional exercise 
capacity and forms part of the Body-mass index, airflow Obstruction, breathlessness (Dyspnea), and 
Exercise (BODE) disease severity score. Daily physical activity measured by accelerometry 
(Average Daily Step count [ADS]) is a patient-centred outcome which may correlate better with 
“real-life” activity.[2] However, people with advanced disease may be unable to complete a 6 
minute walk test (6MWT), or use an accelerometer. In addition, accelerometers may not be 
available in routine clinical practice. 
The Australia-modified Karnofsky Performance Scale (AKPS; online supplement Box 1) is a 
simple, validated measure, useful in advanced disease [3] and can be used across a range of settings. 
AKPS predicts survival and can reflect longitudinal changes.  Although survival may be unaltered 
by a palliative intervention, improvements and/or maintenance in AKPS may allow independent 
living for longer; a highly patient-relevant outcome.  
We investigated the relationship between AKPS and ADS, 6MWD, body mass index (BMI), forced 
expiratory volume in 1 second (FEV1) and the modified Medical Research Council breathlessness 
score (mMRC) in people with advanced disease. We also assessed which was most useful in 
predicting functional independence. 
METHODS 
This exploratory, individual pooled data, cross-sectional analysis used baseline data from seven 
palliative care clinical studies (see Online Supplement Table 1).[4-10]   
In participants with COPD, the variables of interest were the AKPS, ADS, 6MWD, mMRC and 
BODE score (calculated from FEV1, mMRC, BMI and 6MWD data). In participants with lung 
cancer, the variables of interest were AKPS, ADS and 6MWD. 
Ethical considerations 
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National Health Service ethical permission was not required for analysis of pooled anonymised 
data. (http://www.hra.nhs.uk/documents/2013/09/does-my-project-require-rec-review.pdf) 
Appropriate ethics approval and consent had been obtained for each contributing study.  
Statistical analysis 
Descriptive statistics present the participant population and performance status scores observed. 
Spearman correlations were used to measure the strength of the relationship between AKPS and the 
measures of physical activity, performance status and breathlessness. Receiver Operator 
Characteristic (ROC) curves were used to plot the sensitivity versus 1-specificity across varying 
cut-offs.  A cut point of >70 (80 = normal activity with effort; some signs or symptoms of disease) 
for AKPS was chosen as this is the level below which a patient’s daily independence is 
compromised. This was repeated using a cut point of < 60 (50 = considerable assistance and 
frequent medical care required) as this represents a large degree of care dependency.[3] The Area 
Under the Curve (AUC) with standard error and 95% confidence intervals (CI) were calculated. In 
determining optimal cut off values, the Youden index uses the maximum of vertical distance of 
ROC curve from the point (x, y) on diagonal line (chance line) which gives equal weight to 
sensitivity and specificity with no ethical, cost and prevalence constraints.[11]  
All analyses were conducted with STATA SE (StataCorp. 2015. Stata Statistical Software: Release 
14. College Station, TX: StataCorp LP). 
 
RESULTS 
Online Supplement Tables 1 and 2 summarize the study population (n=229) and distribution for the 
variables studied.  The average age of the COPD group and lung cancer group was 69.9 years and 
66.7 years respectively. Around half of the COPD group (34%) and lung cancer group (66%) were 
male. COPD patients were on average overweight (mean BMI 26.1, SD 6.1), with severe or very 
severe lung function impairment (44% <30%pred), and limited by breathlessness on exertion (57% 
mMRC 3 or 4) and activities of daily living. Lung cancer patients were younger and had a better 
performance status than the COPD group, even though over half (55%) had metastatic disease. 
Fewer data about breathlessness on exertion and lung function were available for the lung cancer 
group. ADS count was greater in the lung cancer group (mean 4040, SD 2707), compared with the 
COPD group (mean 2515, SD 1896).   
AKPS in COPD 
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There was a statistically significant positive relationship between AKPS and ADS (r = 0.568, 
p<0.001, n=74) and 6MWD (r = 0.374, p=0.001, n=76). There was a weak correlation with mMRC 
(r= -0.022, p=0.850, n=76) and a statistically significant negative relationship BODE score (r=-
0.363, p=0.001, n=76).  
11/76 (15%)) had a cut-off for AKPS of >70. The ROC curve using ADS showed an area under the 
curve (AUC) of 0.88 (0.04, 95% CI: 0.79 to 0.97). The optimal ADS cut-point was 3342, which 
gave a sensitivity of 81.8% and a specificity of 76.2%. The AUC for 6MWD was 0.76 (0.07, 95% 
CI: 0.62 to 0.90) with an optimal cut off of 242m, which gave a sensitivity of 72.7% and a 
specificity of 33.9%. The AUC was low for the mMRC (0.44 [0.09], 95% CI: 0.26 to 0.62) and 
BODE classification (0.27 [0.07], 95% CI: 0.13 to 0.40).  (Figure 1). 
37/76 (49%)) had a cut-off for AKPS of <60. The ROC curve using ADS had an area AUC of 0.81 
(0.06, 95% CI: 0.69 to 0.93). The optimal ADS cut-point was 1333, which gave a sensitivity of 
72.1% and a specificity of 76.9%. The AUC for 6MWD was 0.64 (0.09, 95% CI: 0.47 to 0.82), with 
an optimal cut-point of 203m, which gave a sensitivity of 75.8% and a specificity of 38.5%. The 
AUC was low for mMRC (0.53 [0.09], 95% CI: 0.36 to 0.71) and for the BODE classification was 
low (0.37 [0.08], 95% CI: 0.21 to 0.54). The ROC graphs are shown in Figure 1.  
AKPS in Lung Cancer 
There was a statistically significant relationship between AKPS and ADS (r = 0.499, p<0.001, 
n=141) and 6MWD (r = 0.916, p<0.001, n=21). Three-quarters (105/140 (75%)) had an AKPS of 
>70. The ROC curve using ADS showed an AUC of 0.72 (0.04, 95% CI: 0.64-0.81. The optimal 
ADS cut- point was 3380, which gave a sensitivity of 60.8% with a specificity of 74.4%. The ROC 
curve is shown in Supplementary Figure 1. For 6MWT the AUC was 1.00. In this sample, there 
were no patients with AKPS < 60 at baseline.  
DISCUSSION 
AKPS (the level of functional independence) is associated with ADS (steps taken in everyday 
living) and, to a lesser degree, to 6MWD (a measure of functional exercise capacity). In terms of the 
physical activity measures predicting independent function (AKPS >70), ADS has a better balance 
of sensitivity and specificity. The AUC for the 6MWD was high but the optimal cut-off 
demonstrated low specificity. To our knowledge, this is the first study to explore the usefulness of 
AKPS as an indication of physical activity capacity. 
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Strengths and limitations of the 6MWD have been reviewed.[2] The distance a patient can walk 
under test circumstances, does not necessarily relate to the ability to function in everyday activities 
which requires a broader set of skills and coping mechanisms.  
Physical activity measures are good predictors of survival.[12] The discrepancy between “classic” 
measures assessed in COPD patients like FEV1, 6MWD and patient-centered outcomes like quality 
of life and activities of daily living has been noted.[12]  Few therapeutic trials also measure changes 
in daily physical activity. Accelerometers might be useful to provide patients with a real-time 
physical activity feedback, leading to a virtuous circle of maintaining or regaining condition.[13] 
Consensus about accelerometers and measures is developing.[14] 
Strengths and limitations 
The combination of data increases generalisability and increased the power of the analysis. 
However, there was significant missing data for some outcomes of interest. For example, in the 
COPD group 37.9% of patients had no spirometry values recorded. In the lung cancer group, 
spirometry was not performed in two-thirds of patients and 6MWD was unavailable in most 
potentially over-estimating the cut points. Also data regarding stage and previous cancer treatment 
of lung cancer was missing for some studies. The utility of the 6MWD in people with lung cancer, 
should be tested on larger datasets. These are cross-sectional data and need confirmation with 
prospectively collected longitudinal data.  
Implications for clinical practice and research 
It is important that measures are minimally burdensome and simple to use. Our data indicate that the 
6MWT may be less relevant in advanced disease, reflecting other prospective, cross-sectional 
measures.[15] 
The ADS appears to be more useful but may still be impractical for many with advanced disease 
especially in clinical practice. Our data indicate a useful and strong relationship with AKPS, therefore, 
if accelerometry is deemed not possible, AKPS would be a useful and practical measure to use instead.  
If accelerometry is possible, people whose ADS which falls < 3300 are likely to be those with an 
AKPS of <70, the level at which independence becomes compromised. Those with an ADS of < 
1300 are likely to be those with an AKPS <60; those becoming more unwell and may benefit from 
palliative care support.    
CONCLUSIONS 
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AKPS is strongly related to ADS in people with lung cancer and COPD. ADS may identify patients 
at risk of losing functional independence and in need of enhanced rehabilitation. The AKPS may be 
useful in clinical practice and research to indicate levels of physical activity where ADS and 6MWT 
are not possible. 
 
FUNDING  
This research did not receive any specific grant from funding agencies in the public, commercial, or 
not-for-profit sectors.  
COMPETING INTEREST: None declared.CONTRIBUTIONS 
Concept and design MJ, MM, DC; data pooling CR, CB; analysis VA, CB; first draft of manuscript 
CB; all authors contributed substantially to data interpretation, manuscript drafts and approved the 
final manuscript. 
ACKNOWLEDGEMENTS 
We would like to acknowledge the contribution the late Prof Ken Fearon of the University of 
Edinburgh in the included studies. 
 
ROLE of SPONSOR 
Not applicable for this secondary analysis 
 
 
FIGURE LEGENDS 
Figure 1a: Receiver Operator Characteristic (ROC) curves for COPD patients calculated with 
Average Daily Steps, 6MWD and BODE with AKPS score greater than 70. 
Figure 1b: Receiver Operator Characteristic (ROC) curves for COPD patients calculated with 
Average Daily Steps, 6MWD and BODE with AKPS score less than 60. 
Online Supplement Figure 1: Receiver Operator Characteristic (ROC) curves for Lung cancer 
patients calculated with Average Daily Steps with AKPS score greater than 70. 
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Online Supplement Box 1: Australia-modified Karnofsky Performance Scale (AKPS) 
assessment criteria 3 
 
AKPS assessment criteria  
 
SCORE  
 
Normal: no complaints; no evidence of disease 
Able to carry on normal activity; minor sign of symptoms of disease 
Normal activity with effort; some signs or symptoms of disease 
Cares for self; unable to carry on normal activity or to do active work 
Able to care for most needs; but requires occasional assistance 
Considerable assistance and frequent medical care required 
In bed more than 50% of the time 
Almost completely bedfast 
Totally bedfast and requiring extensive nursing care by professionals 
and/or family 
Comatose or barely rousable 
Dead 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
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 Online Supplement Table 1. Contributing studies: design, participants, measures 
 
Author Design of study Participants Setting mMRC AKPS 6MWD ADS 
Johnson MJ  
et al 4 
RCT phase II  
international, 
multicentre, trial  
efficacy of a 
hand-held fan and 
exercise advice 
with advice alone 
in increasing 
activity 
 
N = 49 
(M/F  26/23) 
Diagnoses: 
COPD (55%) 
Lung Cancer (10%) 
Asthma (10%) 
Cardiovascular 
Disease (8%) 
Others (17%) 
 
Outpatient 49 49 48 44* 
Maddocks 
M et al 5 
Cohort study, 
patients 
randomized to 
wear ActivePAL 
2 vs. 4 vs. 6 days 
60 
(M/F 40/20) 
Lung and pleural 
cancer (97%) 
Upper Gastro-
intestinal cancer 
(3%)  
Outpatient 
hospital or 
home visits 
0 60 0 59 
Maddocks 
M et al 6 
RCT, NMES of 
quadriceps and 
usual care vs. 
Usual care 
 
16 
(M/F  9/7) 
Lung and pleural 
cancer (100%) 
post-palliative 
chemotherapy  
Cancer clinic,  
ADS assessed 
in free living 
conditions, 
before RCT 
intervention 
0 16 0 15 
Maddocks 
M et al 7 
RCT, phase II, 
double centre 
NMES of 
quadriceps and 
palliative 
chemotherapy vs 
49 
(M/F    28/21) 
Advanced NSCLC 
(100%)  
 
Inpatient, but 
ADS assessed 
in free living 
conditions, 
before RCT 
intervention  
0 49 0 47 
palliative 
chemotherapy 
Maddocks 
M et al 8 
RCT,  double 
blind,  3 centres, 
NMES vs placebo 
 
52 (M/F   21/31) 
COPD (100%)  
 
Palliative 
care 
meetings, 
pulmonary 
rehabilitation 
services. 
49 49 52 49 
Ferrioli E 
et al 9 
Validation of PA 
monitoring as a  
responsive 
outcome measure 
at different stages 
of disease 
 
164 
(M/F  69/94) 
Cancer* 
6 (3%) with lung 
cancer all receiving 
palliative 
radiotherapy 
Outpatients, 
candidate to 
surgery/ 
chemotherapy
/radiotherapy, 
before 
intervention 
0 53 0 161 
Maddocks 
M et al 10 
Cross sectional 
study to 
investigate 
skeletal muscle 
dysfunction 
 
16 
(M/F  7/9) 
Lung and pleural 
cancer (100%)  
palliative 
chemotherapy, 
immunotherapy 
Outpatients, 
hospital visits 
16 16 16 16 
 
RCT: randomized controlled trial; NMES: neuro-muscular stimulation; COPD: Chronic 
Obstructive Pulmonary Disease;, mMRC: modified Medical Research Council scale, AKPS: 
Australian-modified Karnofsky Performance status Scale (research nurse-rated); 6MWD: 6 
minute walking test; ADS: average Daily steps measured by accelerometry (* mean of at 
least 3 days monitoring available across the studies; ActivPAL monitor); NSCLC: non small 
cell lung cancer * Complete data regarding the primary cancer site was not available; 6 
participants known to have lung cancer, all undergoing palliative chemotherapy, were 
included 
 
  
Online Supplement Table 2: Individual pooled data analysis study population (mean 
(SD) or n (%)) 
 
 COPD (n=79) Lung Cancer (n=147) 
Gender 
Male 
Female 
 
36 (45%) 
43 (55%) 
 
87 (60%) 
60 (40%) 
Age (mean (sd) n) 69.6 (9.4) 79 66.7 (9.7) 147 
BMI (mean (sd) n) 26.4 (6.1) 52 25.5 (4.3) 76 
FEV1%pred (mean (sd n) 
>80% no flow limitation 
>80% with flow limitation 
80-50%pred. 
50-30%pred. 
<30%pred. 
Data not available 
28.9 (15.1) 49 
- 
1   (1.3%) 
4   (5.1%) 
9   (11.4%) 
35 (44.3%) 
30 (37.9%) 
76.7 (25.6) 48 
16 (10.9%) 
9   (6.1%) 
18 (12.2%) 
5   (3.4%) 
1   (0.7%) 
98 (66.6%) 
FVC%pred (mean (sd) n) 59.2 (22.3) 49 93.7 (27.6) 47 
mMRC (mean (sd) n) 
1 
2 
3 
4 
Data not available 
2.7 (0.6) 79 
- 
34 (43%) 
38 (48%) 
7   (9%) 
-    (0%) 
2.2 (0.8) 21 
4 (2.7%) 
8 (5.4%) 
9 (6.1%) 
- 
126 (85.7%) 
AKPS (mean (sd) n) 
40 
50 
60 
70 
80 
90 
100 
Data not available 
64.7 (10.3) 76 
1    (1.2%) 
12  (15.1%) 
26  (32.9%) 
26  (32.9%) 
9    (11.4%) 
2   (2.5%) 
-    (0%) 
3   (3.8%) 
81.1 (10.0) 146 
- 
- 
7    (4.7%) 
34  (23.12%) 
53  (36.05%) 
41  (27.9%) 
11  (7.5%) 
1    (1%) 
BODE Index (mean (sd) n) 1.7 (1.0) 79 - 
6MWD (mean (sd)n) 216 (96) 79 375 (140) 21 
ADS (mean (sd)) 2515 (1896) 74 4040 (2707) 142 
 
BMI Body Mass Index, FEV1 Forced Expiratory Volume in the first second, mMRC 
modified Medical research Council dyspnoea scale,  AKPS Australia-modified Karnofsky 
Performance Scale, BODE Body-mass index, airflow Obstruction, Breathlessness, and 
Exercise score, 6MWD 6-minute walking distance 
 
 
